Systematic review of clinical practice guidelines for the diagnosis and management of retinal vein occlusion.

Autor: Galvez-Olortegui J; Evidence Based Ophthalmology Unit (Oftalmoevidencia), Scientia Clinical and Epidemiological Research Institute, Trujillo, Peru. jgalvezo@scientiaceri.com.; Service of Ophthalmology, Hospital Universitario Central de Asturias, Oviedo, Spain. jgalvezo@scientiaceri.com.; Universidad Nacional de Tumbes, Tumbes, Peru. jgalvezo@scientiaceri.com., Bouchikh-El Jarroudi R; Evidence Based Ophthalmology Unit (Oftalmoevidencia), Scientia Clinical and Epidemiological Research Institute, Trujillo, Peru.; Service of Ophthalmology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.; Department of Surgery, Universidad Autónoma de Barcelona (UAB), Barcelona, Spain., Silva-Ocas I; Evidence Based Ophthalmology Unit (Oftalmoevidencia), Scientia Clinical and Epidemiological Research Institute, Trujillo, Peru.; Centro de Excelencia en Glaucoma, Clinica GO-Vision, Lima, Peru., Palacios-Herrera H; Evidence Based Ophthalmology Unit (Oftalmoevidencia), Scientia Clinical and Epidemiological Research Institute, Trujillo, Peru.; Servicio de Retina y Vitreo, EP Oftalmólogos asociados, Lima, Peru., Cubillas-Martin M; Service of Ophthalmology, Hospital Universitario Central de Asturias, Oviedo, Spain., Zavaleta-Mercado M; Evidence Based Ophthalmology Unit (Oftalmoevidencia), Scientia Clinical and Epidemiological Research Institute, Trujillo, Peru.; Instituto de Investigaciones Oftalmológicas y Ciencias Visuales Avanzadas Zavaleta Mercado (Innovaz), Oruro, Bolivia., Burgueño-Montañes C; Evidence Based Ophthalmology Unit (Oftalmoevidencia), Scientia Clinical and Epidemiological Research Institute, Trujillo, Peru.; Service of Ophthalmology, Hospital Universitario Central de Asturias, Oviedo, Spain., Galvez-Olortegui T; Evidence Based Ophthalmology Unit (Oftalmoevidencia), Scientia Clinical and Epidemiological Research Institute, Trujillo, Peru.; Centro de Excelencia en Glaucoma, Clinica GO-Vision, Lima, Peru.; Department of Ophthalmology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.
Jazyk: angličtina
Zdroj: Eye (London, England) [Eye (Lond)] 2024 Jun; Vol. 38 (9), pp. 1722-1733. Date of Electronic Publication: 2024 Mar 11.
DOI: 10.1038/s41433-024-03008-1
Abstrakt: Background/objectives: To assess the methodological quality of Clinical Practice Guidelines (CPG) for the diagnosis and management of Retinal Vein Occlusion (RVO).
Methods: A systematic review of CPGs for the diagnosis and management of RVO was carried out with a search in databases, metasearch engines, CPG development institutions, ophthalmology associations and CPG repositories until April 2022. Search update was performed on April 2023, with no new record available. Five CPGs published in the last 10 years in English/Spanish were selected, and 5 authors evaluated them independently, using the Appraisal of Guidelines for Research and Evaluation (AGREE-II) instrument. An individual assessment of each CPG by domain (AGREE-II), an overall assessment of the guide, and its use with or without modifications were performed. Additionally, a meta-synthesis of the recommendations for the most relevant outcomes was carried out.
Results: The lowest score (mean 18.8%) was for domain 5 'applicability', and the highest score (mean 62%) was for domain 4 'clarity of presentation'. The 2019 American guideline (PPP) presented the best score (40.4%) in domain 3 'rigour of development'. When evaluating the overall quality of the CPGs analysed, all CPGs could be recommended with modifications. In the meta-synthesis, anti-VEGF therapy is the first-choice therapy for macular oedema associated with RVO, but there is no clear recommendation about the type of anti-VEGF therapy to choose. Recommendations for diagnosis and follow-up are similar among the CPGs appraised.
Conclusion: Most CPGs for the diagnosis and management of RVO have a low methodological quality assessed according to the AGREE-II. PPP has the higher score in the domain 'rigour of development'. Among the CPGs appraised, there is no clear recommendation on the type of anti-VEGF therapy to choose.
(© 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
Databáze: MEDLINE
Externí odkaz: